We should try to remove barriers that are not only in place, but getting higher for clinicians and patients to get evidence-based care, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
We should try to remove barriers that are not only in place, but getting higher for clinicians and patients to get evidence-based care, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Transcript (slightly modified)
I think there is a role for clinically nuanced or value-based insurance design in oncology given that current plans, both public and private, have what I call 1 size fits all cost-sharing and that you pay for same for every doctor’s visit, every diagnostic test, and every prescription drug. I like to say that Americans pay the same co-insurance for specialty drugs that cure cancers 90% of the time as drugs that never cure a case. That doesn’t make any sense to me; so, I think that this idea of setting cost-sharing based on value, not price, is important to move forward in general, and specifically in the role of cancer care, because cancer is: A. very complicated, B. very emotional, and C. it’s one that exemplifies this idea of our need for a dynamic, or a precision type of benefit design. So, if for instance we have a particular cancer, which has a genetic marker for which there is a specific treatment, I think it should be easy, not hard, for a practitioner to prescribe that targeted therapy, and it should be easy, not hard and not too expensive, for the patient to get that therapy.
When you realize that there are some issues of equity that everyone should have the same type of benefit design, I think that falls directly in the face of what we’re trying to do with precision or personalized medicine. Not that we have to go so far that everyone has a different benefit design, but I’d like to see a benefit design that reflects: A. the amazing innovation that we have going on regarding precision diagnostics and therapies and B. understanding that unless the delivery system evolves to account for this amazing innovation, we’re going to be left behind in a situation that’s not precise or nuanced at all, and that we won’t be able to take advantage of the opportunities that we have as clinicians to improve individual and population health.
In the end, we don’t want to let the perfect get in the way of the good, but we should clearly try to remove those barriers that are not only in place, but getting higher for clinicians and patients to get evidence-based care as outlined say by some well-established guidelines. I think if we started with a few examples in oncology the same way we did with diabetes and heart disease and value-based insurance design in general, we’ll be able to infuse the idea of nuanced or VBID into the care of cancer. So, we might be able to improve access to care, allow providers to have autonomy to provide the evidence-based care they want, but also being very cognizant of the fiscal responsibilities we have toward public and private payers.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More